Bigelow Investment Advisors LLC Boosts Stock Position in Novo Nordisk A/S $NVO

Bigelow Investment Advisors LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 6.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,084 shares of the company’s stock after buying an additional 200 shares during the quarter. Bigelow Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $213,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Copeland Capital Management LLC increased its position in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter worth $27,000. Park Square Financial Group LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $29,000. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $30,000. Finally, Disciplina Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Up 1.7%

NYSE NVO opened at $58.20 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. The firm has a market cap of $259.86 billion, a PE ratio of 15.99, a P/E/G ratio of 2.17 and a beta of 0.66. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $135.20. The firm’s fifty day moving average is $57.21 and its two-hundred day moving average is $65.81.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s payout ratio is 22.53%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 20th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, HSBC lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price target on the stock. in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $81.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.